Cell2B is granted Orphan Designation for Prevention of GvHD

09 January 2015 — FacebookLinkedInEmail

Cell2B is granted Orphan Medical Product Designation EU/3/14/1388 for Prevention of Graft-versus-Host Disease (GvHD) by the European Commission upon positive opinion by the Committee for Orphan Medicinal Products. This new designation comes on top of Orphan Designation for GvHD treatment granted in 2013 (EU/3/13/1129). Cell2B is strongly committed to deliver new therapies that tackle this unmet clinical need. GvHD is the lead indication of a larger set of immune indications Cell2B is addressing. More information here.